Marshall University

Marshall Digital Scholar
Gastroenterology

School of Medicine

Fall 11-25-2015

Recurrent Hepatocellular Carcinoma in Patient
with Crohn’s Disease: Incidental or Expected
Outcome of Azathioprine?
Youssef Botros
Mary Mathews
Hiren Patel
Nihar Shah MD
Marshall University, shahn@marshall.edu

Walid Baddoura
See next page for additional authors

Follow this and additional works at: http://mds.marshall.edu/sm_gastro
Part of the Gastroenterology Commons
Recommended Citation
Botros Y, Mathews M, Patel H, Shah N, Baddoura W, de la Torre A. Recurrent Hepatocellular Carcinoma in Patient with Crohn’s
Disease: Incidental or Expected Outcome of Azathioprine?. Case Reports in Gastrointestinal Medicine. 2015 Dec 14;2015.

This Article is brought to you for free and open access by the School of Medicine at Marshall Digital Scholar. It has been accepted for inclusion in
Gastroenterology by an authorized administrator of Marshall Digital Scholar. For more information, please contact zhangj@marshall.edu,
martj@marshall.edu.

Authors

Youssef Botros, Mary Mathews, Hiren Patel, Nihar Shah MD, Walid Baddoura, and Andrew de la Torre

This article is available at Marshall Digital Scholar: http://mds.marshall.edu/sm_gastro/10

Hindawi Publishing Corporation
Case Reports in Gastrointestinal Medicine
Volume 2015, Article ID 939136, 4 pages
http://dx.doi.org/10.1155/2015/939136

Case Report
Recurrent Hepatocellular Carcinoma in
Patient with Crohn’s Disease: Incidental or
Expected Outcome of Azathioprine?
Youssef Botros,1 Mary Mathews,1 Hiren Patel,2 Nihar Shah,3
Walid Baddoura,2 and Andrew de la Torre4
1

Department of Internal Medicine, St. Joseph’s Regional Medical Center, New York Medical College, Paterson, NJ 07503, USA
Department of Gastroenterology, St. Joseph’s Regional Medical Center, New York Medical College, Paterson, NJ 07503, USA
3
Department of Gastroenterology, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV 25755, USA
4
Department of General and Hepatobiliary Surgery, St. Joseph’s Regional Medical Center, Paterson, NJ 07503, USA
2

Correspondence should be addressed to Youssef Botros; dr youssefatef@yahoo.com
Received 27 September 2015; Revised 20 November 2015; Accepted 25 November 2015
Academic Editor: Hideto Kawaratani
Copyright © 2015 Youssef Botros et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Hepatocellular carcinoma (HCC) usually occurs in patients with underlying risk factors such as liver cirrhosis and chronic hepatitis
B. Although patients with Crohn’s disease (CD) are at an increased risk to develop malignancies such as colon cancer, the incidence
of HCC in this population is extremely rare. We report a case of 62-year-old male with long history of CD treated with azathioprine
(AZA) and aminosalicylic acid (ASA) who was incidentally diagnosed with HCC, for which left hepatectomy was done. Four
years later during routine follow-up, patient had another hepatic lesion and underwent resection of the mass. The mechanism of
occurrence of HCC in patient with CD is still controversial and may include immune mediated changes and medication related
complications. AZA was reported in all case reports of CD that developed HCC. Through this report we hope to explore the complex
pathophysiological mechanisms contributing to the development of HCC in the Crohn’s disease patient population.

1. Introduction

2. Case Presentation

Hepatocellular carcinoma (HCC) is the sixth most common
neoplasm worldwide, with about 600,000 deaths annually [1].
HCC usually occurs in patients with underlying risk factor,
for example, liver cirrhosis or chronic hepatitis B [2]. Patients
with Crohn’s disease (CD) are at increased risk of developing
cancers, and colon cancer is considered the most important
cause of excess mortality among these patients [3]. The
incidence of HCC in the Crohn’s disease patient population
is extremely rare [4]. There are only few cases of HCC in
patients with CD reported in literature with only one case
reported of recurrent HCC [5]. We report a case of recurrent
HCC in a CD patient without underlying liver disease who
was treated with azathioprine (AZA) and aminosalicylic acid
(ASA).

We present a case of a 62-year-old male with 42-year history
of small intestinal CD diagnosed at the age of 20, requiring
two small bowel resection surgeries during this course of
time. Our patient was solely on prednisone therapy for an
extended period of time and switched to AZA (150 mg daily)
for the last 21 years with relatively well controlled symptoms.
During routine follow-up screening tests, he was incidentally
found to have left lobe liver mass and was diagnosed with
HCC for which he received left lobe hepatectomy at the age
of 58. The AZA dose was reduced to 50 mg daily.
On subsequent follow-up, four years after the initial resection, he was found to have liver mass and was admitted to the
hospital for further evaluation. On presentation to hospital,
the patient appeared well without any evidence of jaundice
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Figure 1: Arterial phase showing 2.2 × 1.6 × 2.1 lesion in segment V.

or stigmata of chronic liver disease. Preoperative blood work
including liver profile and viral hepatitis markers was entirely
normal: AST 18 U/L (<37 U/L), ALT 16 (<60 U/L), albumin
3.5 g/dL (3.5–5 g/dL), bilirubin 0.8 mg/dL (0.3–1.2 mg/dL),
and INR 1.0, alpha-fetoprotein 10.3 ng/mL (<6.1 ng/mL),
prothrombin time 13.3 seconds, and platelet count 210/𝜇L.
Triple phase contrast enhanced CT of abdomen showed
solitary mass in the segment 5 of the right lobe measuring 2.2
× 1.6 × 2.1 cm, with arterial enhancement and early wash out
in the venous phase, and no evidence of lymphadenopathy or
extrahepatic metastasis (Figures 1 and 2).
The decision toward surgical excision of the tumor was
made. Patient underwent laparoscopic resection of segment
5 with no postoperative complications. Microscopically, the
resected mass showed moderately differentiated hepatocellular carcinoma without evidence of microvascular invasion
(Figure 3).
There was no postoperative adverse events and AZA was
discontinued and patient was kept on oral budesonide.

3. Discussion
The occurrence of HCC among patients with CD is extremely
rare, with only about 12 cases reported in the literature [5–16].
Most of the patients with CD who developed HCC received
AZA, with a few cases who did not receive AZA but were
eventually found to have underlying liver disease [9, 15].
The exact mechanism for the occurrence of HCC in
patients with CD without underlying liver disease is not well
established. Is it a pathophysiological outcome of Crohn’s disease itself? Or is it more related to the treatments of CD? The
answers to these scientific queries require further investigations.
AZA use is associated with increased risk of many malignancies including squamous cell skin cancer in patients with
rheumatological diseases and lymphoma among IBD patients
[17, 18]. However, there are no retrospective studies in medical literature reporting any correlation between the use of
AZA and occurrence of HCC in patients with CD.
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Figure 2: Hepatic lesion showing early wash out in venous phase.

There have been only two reported cases of hepatocellular
carcinoma in patients receiving azathioprine for clinical
conditions other than CD, one in patient with ulcerative
colitis and the other case in renal transplant patient [19, 20].
The relation between long term use of AZA and development of HCC is still controversial, and the mechanism by
which AZA can predispose to HCC is thought to be due to
increase in the hepatic cells turnover. Arber et al. demonstrated this effect on animals by injecting rats with AZA and
measuring the distance of labeled liver cells from the portal
space and found increase in the hepatocytes’ and littoral cells’
streaming velocities in the AZA treated rats compared to the
control group. This can possibly lead to aberrant cell growth
via abnormal mechanisms [21]. AZA can also precipitate to
cancers via decreasing the immunity against cancer cells and
increasing the susceptibility to oncogenic viruses [10].
Other possible mechanisms for the occurrence of HCC
in CD patients have been postulated; some endothelial-cell
adhesion molecules and chemokines that are restricted to the
gut under normal condition become abnormally expressed in
the liver in IBD patients. This can lead to immune response
mediated by mucosal T cells, against these antigens and
subsequently hepatic damage [22].
Another reported pathophysiological mechanism is a
correlation between the gut microbiota in patients with CD
and occurrence of HCC. Fox et al. showed that gut microbiota
can define the risk of HCC development in response to
environmental factors including carcinogenic chemicals and
hepatitis virus transgenes. Colonization of gut with harmful
bacteria is thought to alter bowel mucosal integrity facilitating the passage of harmful bacteria to portal circulation.
Also this change in gut microbiota can increase secretion
of cytokines acting on the liver and upregulating the transcription of numerous cytokines and receptors that act as key
regulator of hepatic injury carcinogenesis [23, 24].
In conclusion, there appears to be complex interplay of
pathophysiological mechanisms in patients with CD, leading
to the development of HCC while on AZA therapy.
Gastroenterologist should be aware of this rare association between using AZA in CD and development of HCC.
We hope that this intriguing area receives robust scientific
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Figure 3: Moderately differentiated HCC, hematoxylin and eosin: low power (a) and high power (b and c).

inquiry in order to establish a strong correlation and find out
if patients on AZA for CD should have screening for HCC.
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